Skip to main content

Table 1 Baseline characteristics of patients with metachronous pulmonary metastases from PDAC

From: Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study

Variables  
Age, years, median (range) 69.0 (55.0–80.0)
Sex, n (%)
 Male 15 (56.0)
 Female 9 (44.0)
ECOG performance status, n (%)
 0,1 21 (87.5)
 2,3 3 (12.5)
Location, n (%)
 Head 17 (70.8)
 Body-tail 7 (29.2)
CEA (ng/mL), median (range) 3.9 (1.2–51.5)
CA19-9 (U/mL), median (range) 128.5 (11.0–1185.9)
Neoadjuvant chemotherapy, n (%)
 Gemcitabine + S-1 2 (8.3)
Surgical procedure, n (%)
 PD 17 (70.8)
 DP 7 (29.2)
Portal vein resection, n (%) 6 (25.0)
Primary tumour size (mm), median (range) 31 (6–80)
Pathologic T category (primary tumour), n (%)
 T1 6 (25.0)
 T2 11 (45.8)
 T3 7 (29.2)
Pathologic N category, n (%)
 N0 6 (25.0)
 N1 8 (33.3)
 N2 10 (41.7)
Residual tumour category, n (%)
 R0 21 (87.5)
 R1 3 (12.5)
Tumour differentiation, n (%)
 Well 9 (37.5)
 Moderate 11 (45.8)
 Poor 4 (16.7)
Pathologic UICC stage, n (%)
 1A 5 (20.8)
 1B 1 (4.2)
 2A 0
 2B 8 (33.3)
 3 10 (41.7)
Adjuvant chemotherapy, n (%) 21 (87.5)
S-1 14 (58.3)
Gemcitabine 4 (16.7)
Gemcitabine + S-1 3 (12.5)
  1. PDAC pancreatic ductal adenocarcinoma, PD pancreatoduodenectomy, DP distal pancreatectomy, ECOG Eastern Cooperative Oncology Group, UICC Union for International Cancer Control, CEA carcinoembryonic antigen, CA19-9 colorectal cancer antigen